The Right to Prevent TB
It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.
Mourning Paul Farmer, Honoring His Legacy
TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
TB Vaccine Advocacy Roadmap Calls for Increased EU Funding for TB Vaccine Development
TAG stands proudly alongside the TB community to issue this press statement calling for increasing European funding for TB vaccine development, just before the sixth Global Forum on TB Vaccines convenes in Toulouse, France.
Submission to the Office of the High Commissioner for Human Rights Input to HRC resolution 47/17
On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).
2021 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
2021 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2020 and analyzes trends in funding since 2005.
Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis
After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.